 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
"3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A non-peptide, kappa-opioid receptor agonist which has also been found to stimulate the release of adrenocorticotropin (ADRENOCORTICOTROPIC HORMONE) via the release of hypothalamic arginine vasopressin (ARGININE VASOPRESSIN) and CORTICOTROPIN-RELEASING HORMONE. (From J Pharmacol Exp Ther 1997;280(1):416-21)
| Descriptor ID |
D019900
|
| MeSH Number(s) |
D03.383.773.170
|
| Concept/Terms |
U-50488- U-50488
- U 50488
- U50488
- U-50488H
- U 50488H
- U50488H
- U-50,488H
- U 50,488H
- U50,488H
|
Below are MeSH descriptors whose meaning is more general than "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer".
Below are MeSH descriptors whose meaning is more specific than "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer".
This graph shows the total number of publications written about "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer" by people in this website by year, and whether "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer" by people in Profiles.
-
Heinsbroek JA, Furbish AB, Peters J. A single, extinction-based treatment with a kappa opioid receptor agonist elicits a long-term reduction in cocaine relapse. Neuropsychopharmacology. 2018 06; 43(7):1492-1497.
-
Laman-Maharg AR, Copeland T, Sanchez EO, Campi KL, Trainor BC. The long-term effects of stress and kappa opioid receptor activation on conditioned place aversion in male and female California mice. Behav Brain Res. 2017 08 14; 332:299-307.
-
Tejeda HA, Natividad LA, Orfila JE, Torres OV, O'Dell LE. Dysregulation of kappa-opioid receptor systems by chronic nicotine modulate the nicotine withdrawal syndrome in an age-dependent manner. Psychopharmacology (Berl). 2012 Nov; 224(2):289-301.
-
Chudapongse N, Kim SY, Sasaki K, Kramer RE, Ho IK. Nonopioid receptor-mediated effects of U-50,488H on [Ca(2+)]i and extracellular dopamine in PC12 cells. J Neurosci Res. 2003 Nov 15; 74(4):598-604.
-
Chudapongse N, Kim SY, Kramer RE, Ho IK. Nonspecific effects of the selective kappa-opioid receptor agonist U-50,488H on dopamine uptake and release in PC12 cells. J Pharmacol Sci. 2003 Nov; 93(3):372-5.
-
Bero LA, Lurie SN, Kuhn CM. Early ontogeny of kappa-opioid receptor regulation of prolactin secretion in the rat. Brain Res. 1987 Dec 15; 465(1-2):189-96.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|